Publications by authors named "Yuanmin Zhou"
Article Synopsis
- A study assessed the effectiveness of combining transarterial chemoembolization (TACE) with lenvatinib and tislelizumab for treating patients with advanced intermediate-stage hepatocellular carcinoma (HCC) that does not meet standard criteria.
- Results showed that the combination treatment (TLT group) significantly improved overall survival and progression-free survival compared to TACE alone (T group) and TACE with lenvatinib (TL group).
- Despite a slightly higher incidence of treatment-related adverse events in the combination groups, all side effects were manageable and there were no treatment-related deaths.
Article Synopsis
- The study examines a new treatment approach for patients with unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) using a combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and tislelizumab, with or without transhepatic arterial embolization (TAE).
- Results showed that patients receiving the combined treatment (THLP group) had a higher objective response rate (72% vs 52%) and longer overall survival (median 14.1 months vs 11.3 months) compared to those without TAE (HLP group).
- The study indicates that this combination therapy is feasible and has manageable side effects, making it a
Article Synopsis
- A study compared the effectiveness and safety of combining toripalimab with hepatic arterial infusion chemotherapy (HAIC) against lenvatinib in treating advanced hepatocellular carcinoma (HCC) in patients with severe disease.* -
- Results showed that the TorHAIC group had significantly longer progression-free survival (9.3 months vs. 4.8 months), longer overall survival (17.13 months vs. 10.1 months), and better disease control rates and response rates compared to the lenvatinib group.* -
- Both treatment options were well-tolerated, with no treatment-related deaths, and even after matching patients by propensity scores, results in the TorHAIC group remained superior, indicating
Purpose: In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment responses than transarterial chemoembolization (TACE) in large unresectable hepatocellular carcinoma. We aimed to compare the overall survival of patients treated with FOLFOX-HAIC versus TACE as first-line treatment in this population.
Methods: In this randomized, multicenter, open-label trial, adults with unresectable hepatocellular carcinoma (largest diameter ≥ 7 cm) without macrovascular invasion or extrahepatic spread were randomly assigned 1:1 to FOLFOX-HAIC (oxaliplatin 130 mg/m, leucovorin 400 mg/m, fluorouracil bolus 400 mg/m on day 1, and fluorouracil infusion 2,400 mg/m for 24 hours, once every 3 weeks) or TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles).
Article Synopsis
- Lenvatinib is commonly used as a first-line treatment for advanced hepatocellular carcinoma, but its effectiveness is limited; combining it with toripalimab and hepatic arterial infusion chemotherapy (HAIC) may enhance treatment outcomes.
- A retrospective study involving 157 patients compared the efficacy and safety of lenvatinib alone versus the combination of lenvatinib, toripalimab, and HAIC, assessing factors like progression-free survival and overall survival.
- Results showed that the combination treatment (LeToHAIC group) significantly outperformed lenvatinib alone in terms of progression-free survival (11.1 months vs. 5.1 months) and overall survival, but also had higher rates of serious side
Importance: Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patients in a previous phase 2 study.
Objective: To investigate the efficacy and safety of sorafenib plus HAIC compared with sorafenib for hepatocellular carcinoma with portal vein invasion.
Hierarchical Self-Assembly of CuTe Nanorods into Superstructures with Enhanced SERS Performance.
ACS Appl Mater Interfaces
December 2016
This paper reports a strategy to get self-assembly of CuTe nanorods into hierarchical superstructures: the side-by-side self-assembly of nanorods into microscale one-dimensional (1D) nanowires (primary structure), the side-by-side alignments of the 1D nanowires into two-dimensional (2D) nanowire bundles (secondary structure), and the further rolling up of the 2D bundles into three-dimensional (3D) microtubes (tertiary structure). It was found that the oleylamine (OLA)/n-dodecanethiol (DDT) mixture as a binary capping agent was key to produce CuTe nanorods in the quantum size regime with high monodispersity, and this was a prerequisite for their hierarchical self-assembly based on elaborate control of the solvent evaporation process. The obtained CuTe microtube superstructures were used as SERS substrate and showed much stronger SERS enhancement than the as-prepared CuTe nanorods before assembly.
View Article and Find Full Text PDFParasitic diseases are of enormous public health significance in developing countries-a situation compounded by the toxicity of and resistance to many current chemotherapeutics. We investigated a focused library of 18 structurally diverse bis-acridine compounds for in vitro bioactivity against seven protozoan and one helminth parasite species and compared the bioactivities and the cytotoxicities of these compounds toward various mammalian cell lines. Structure-activity relationships demonstrated the influence of both the bis-acridine linker structure and the terminal acridine heterocycle on potency and cytotoxicity.
View Article and Find Full Text PDF